All News

RAMPART shows early quality-of-life declines with adjuvant Imfinzi and Imjudo, improving over time, though later cognitive and pain effects emerge.

Living long-term with cancer means learning to live in chapters. There are calm chapters and uncertain ones. Seasons of stability and seasons of intervention.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

Phase 2 INDIBLADE data support Yervoy and Opdivo before bladder-sparing chemoradiotherapy.

Keytruda plus paclitaxel improved overall survival by 18% in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

Overview of nodular sclerosis Hodgkin lymphoma, including diagnosis, staging, treatment options by stage and possible side effects.

Keytruda/Welireg and Welireg/Lenvima combinations show improved survival and disease control in kidney cancer, according to new data from ASCO GU.

Keytruda plus Welireg lowered the risk of recurrence in high-risk clear cell kidney cancer after surgery.

Welireg plus Lenvima improved outcomes compared with versus Cabometyx in advanced clear cell renal cell carcinoma after immunotherapy.

Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials.

Disitamab vedotin demonstrated responses in previously treated HER2-expressing advanced urothelial carcinoma, with activity across HER2 expression levels.

Adding cabazitaxel to hormone therapy and radiation did not improve survival and caused more side effects in high-risk localized prostate cancer.

Padcev plus Keytruda before and after surgery helped more bladder cancer patients live longer and remain cancer-free than standard chemotherapy.

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase 3 genitourinary cancer trials.

Dr. Eric Singer discusses rising early-onset kidney cancer, the role of hereditary syndromes like VHL, and lifestyle tips for patients under age 50.

Adding 177Lu-PSMA-617 to combination therapy improves disease control in PSMA+ mHSPC while maintaining quality of life and pain outcomes.

Dr. Ranee Mehra shares guidance on recurrence, quality-of-life concerns and clinical trials for patients with head and neck cancers and caregivers.

Six years after a colon cancer diagnosis, Carla Deschamps reflects on growth, independence and optimism shaped by survivorship.

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Subcutaneous Rybrevant plus Keytruda led to a 56% response rate in recurrent or metastatic head and neck cancer in OrigAMI-4.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained.

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a Phase 3 clinical trial.

Majority of Americans say they don’t have time for colorectal cancer screening, prioritizing household chores instead of their health.

Daily practices help one writer find calm and stability while living with multiple myeloma.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.